Skip to main content
SpringerLink
Log in

Rivastigmine to treat delirium harmful in the critically ill

  • Clinical study
  • Published:
Reactions Weekly Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

REFERENCE

  1. van Eijk MJ, Roes KCB, Honing MLH, Kuiper MA, Karakus A, van der Jagt M, Spronk PE, van Gool WA, van der Mast RC, Kesecioglu J, Slooter AJC.Effect of rivastigmine as an adjunct to usual care with haloperidol on duration of delirium and mortality in critically ill patients: a multicentre, double-blind, placebo-controlled randomised trial. Lancet: [9 pages], 5 Nov 2010. Available from: URL: http://dx.doi.org/10.1016/S0140-6736(10)61855-7

  2. Skrobik Y.Delirium treatment: an unmet challenge. Lancet: [3 pages], 5 Nov 2010. Available from: URL: http://dx.doi.org/10.1016/S0140-6736(10)61998-8

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

Rivastigmine to treat delirium harmful in the critically ill. React. Wkly. 1328, 1 (2010). https://doi.org/10.2165/00128415-201013280-00001

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00128415-201013280-00001

Keywords

Search

Navigation